785 articles
A phase III trial shows ensitrelvir slashes COVID infection risk in household contacts, with potential use in nursing homes.
Tumor-infiltrating lymphocyte therapies are emerging as a powerful cancer treatment. Here's what the science says and why it matters for longevity.
Subtle speech habits like pauses and filler words predict cognitive decline, with AI spotting signs traditional tests often miss.
A 43-year study of 131,000+ adults found moderate caffeine intake cuts dementia risk by 35% — but more isn't better.
A new annual report reveals a surging Alzheimer's drug pipeline targeting inflammation, tau, and amyloid across 192 active trials.
COYA 302 combines low-dose IL-2 and CTLA-4 Ig to boost regulatory T cells and curb ALS-driving inflammation, now on an expedited FDA path.
LW-1017, a novel small molecule targeting autophagy-lysosomal pathways, enters Phase 1 trials for neurodegenerative disease treatment.
Sironax's SARM1 inhibitor SIR2501 wins FDA Fast Track status for chemotherapy-induced nerve damage, with trials also targeting ALS.
MBX 4291 delivered 7% average weight loss in 8 weeks with minimal nausea — and could replace weekly GLP-1 injections with once-monthly dosing.
WHOOP is adding in-app telehealth this summer, letting clinicians analyze your continuous biometric data alongside medical records and lab work.
Three new NIH-funded findings tackle metabolic aging, cardiovascular risk, and a surprising hormonal brake on brain tumors.
Scientists found drugs that kill senescent 'zombie cells' by blocking their key survival protein, shrinking tumors in mice.
